3. Zoetis Inc. (NYSE:ZTS)
Price Target Upside: 35.24%
Zoetis Inc. (NYSE:ZTS) is a global animal health company that focuses on the discovery, development, manufacture, and commercialization of vaccines, medicines, biodevices, genetic tests, diagnostic products, and precision animal health. It stands third among the best weight loss drugs to buy according to analysts.
Zoetis Inc. (NYSE:ZTS) is addressing pet obesity through various products and initiatives. For dogs, it developed Slentrol (dirlotapide), the first FDA-approved medication for canine obesity. This drug works by reducing appetite and food intake, with studies showing a mean weight loss of 11.8% over four months.
For cats, the company offers products like CliniCare RF Feline Liquid Diet with renal impairment and Rebound Recuperation Formula, a low-calorie liquid supplement to support healthy eating during recovery.
Zoetis Inc. (NYSE:ZTS) has also developed diagnostic tools like Vetscan Imagyst, an AI-powered system to monitor pets’ health during weight loss programs. The corporation promotes pet owner education through initiatives like BARC (Body Assessment Rating for Canines) and encourages communication with veterinarians about weight management. Ongoing research and development efforts are focused on advancing pet health solutions.
Zoetis Inc. (NYSE:ZTS) had a strong financial year, with a total revenue of $9.3 billion, reflecting an 8% increase overall and 11% growth in operational revenue. The companion animal portfolio saw significant growth, especially with products like Simparica and Librela. Revenue from livestock also increased, which was driven by innovative vaccines and solutions. The company’s profitability improved, with adjusted net income rising 10% to $2.7 billion. Key drivers of growth included popular treatments for pet arthritis and skin conditions, as well as a strong performance in the U.S. and international markets. Looking ahead, Zoetis Inc. (NYSE:ZTS) expects continued growth in 2025, with revenue and net income projected to increase by 6% to 8%.
